Compare NYC & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYC | CDT |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 22.1M |
| IPO Year | 2014 | N/A |
| Metric | NYC | CDT |
|---|---|---|
| Price | $8.35 | $2.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.1K | ★ 68.8K |
| Earning Date | 04-15-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $56.73 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.03 | $0.37 |
| 52 Week High | $16.30 | $11.00 |
| Indicator | NYC | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 50.52 | 43.05 |
| Support Level | $8.14 | $1.31 |
| Resistance Level | $8.88 | $2.30 |
| Average True Range (ATR) | 0.29 | 0.40 |
| MACD | 0.05 | -0.29 |
| Stochastic Oscillator | 50.00 | 1.97 |
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The group is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.